申请人:CMG Pharmaceutical Co., Ltd.
公开号:US09422298B2
公开(公告)日:2016-08-23
The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.
该发明提供了新型的取代吡啶并嘧啶化合物,其代表式为I式或其药学上可接受的盐、溶剂和多晶体、酯、互变异构体或前药,以及包含这些化合物的组合物。所提供的化合物可用作磷脂酰肌醇3′ OH激酶家族(PI3K)的抑制剂,用于治疗炎症性疾病、癌症、心血管疾病、过敏、哮喘和自身免疫性疾病。